The Hackett Group (HCKT) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 total revenues reached $77.7 million, up from $77.1 million in Q2 2023, with revenues before reimbursements at $75.9 million, exceeding guidance and driven by Oracle and SAP segment overperformance.
Net income for Q2 2024 was $8.7 million ($0.31 per diluted share), nearly flat year-over-year; adjusted EPS was $0.39, at the high end of guidance.
Cash flow from operations improved to $16.5 million for the first six months of 2024, with Q2 cash flow at $13.7 million, up from $7.7 million year-over-year.
Significant investments in Gen AI, including the launch of AI XPLR Version 2, are expanding client engagement and positioning for future growth.
Oracle and SAP Solutions segments showed revenue growth, while Global S&BT declined due to extended client decision-making cycles.
Financial highlights
Adjusted EBITDA was $16.3 million (21.5% of revenues before reimbursements), nearly flat year-over-year.
Operating income for Q2 2024 was $12.5 million, slightly down from $12.8 million in Q2 2023.
SG&A costs increased 3% in Q2 2024 to $18.0 million, reflecting investments in program development and sales resources.
Interest expense declined to $0.5 million in Q2 2024 from $0.9 million in Q2 2023, with outstanding debt reduced to $27.0 million.
Cash balance at June 28, 2024 was $19.1 million; $12.9 million remains authorized for share repurchases.
Outlook and guidance
Q3 2024 revenues before reimbursements expected between $74.5 million and $76 million, reflecting typical seasonal softness.
Adjusted diluted EPS for Q3 2024 guided to $0.39–$0.41; adjusted gross margin expected at 43–44%.
Dividend of $0.11 per share declared for Q3 2024, payable October 4, 2024.
Management expects available funds and cash flows from operations to be sufficient for at least the next twelve months.
Latest events from The Hackett Group
- Annual meeting to vote on director, stock plan amendment, compensation, and auditor ratification.HCKT
Proxy filing20 Mar 2026 - Proxy covers director election, compensation, stock plan amendment, and auditor ratification.HCKT
Proxy filing20 Mar 2026 - Q4 2025 beat guidance with SAP and GenAI gains, but margins and EBITDA declined year-over-year.HCKT
Q4 202517 Feb 2026 - Q3 revenue and adjusted EPS beat guidance; GenAI growth accelerated by LeewayHertz acquisition.HCKT
Q3 202417 Jan 2026 - Q4 results beat guidance on SAP and GenAI strength; GenAI investments to drive 2025 growth.HCKT
Q4 202423 Dec 2025 - Shareholders will vote on director elections, stock plan expansion, executive pay, and auditor ratification.HCKT
Proxy Filing2 Dec 2025 - Annual meeting to vote on directors, stock plan amendment, compensation, and auditor.HCKT
Proxy Filing2 Dec 2025 - Q2 revenue up 1.6% to $78.9M; Gen AI drives growth, but costs weigh on net income.HCKT
Q2 202523 Nov 2025 - GenAI-fueled growth drove strong Q1 results, despite lower net income from higher expenses.HCKT
Q1 202521 Nov 2025